Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis
Current Medical Research and Opinion, 06/23/09
Chiao E et al. - Natalizumab was the most cost-effective therapy as measured by total cost per relapse avoided, not withstanding a higher drug acquisition cost versus other DMTs. Entry of natalizumab to the market is likely to result in a minimal increase in health-plan costs on a PMPM basis. Limitations of the study include the use of a surrogate measure, relapse avoided, as an outcome measure; also, adverse events were not included in the model.
Related Articles
APOE-epsilon4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis
Multiple Sclerosis, 11/19/09
Relevance Score: 69%
Early Psychiatric Manifestation in a Patient with Primary Progressive Multiple Sclerosis
Archives of Iranian Medicine, 11/12/09
Relevance Score: 69%
Cochlear implantation in a profoundly deaf patient who also suffers from multiple sclerosis - a case study
Cochlear Implants International, 10/27/09
Relevance Score: 69%
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Multiple Sclerosis, 10/01/09
Relevance Score: 69%
Early Drug Treatment May Cut Multiple Sclerosis Risk
MedLinePlus, 10/08/09
Relevance Score: 68%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Modafinil for multiple sclerosis fatigue: Does it work
Clinical Neurology and Neurosurgery, 12/18/09
Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry in six countries
Current Medical Research and Opinion, 12/18/09
Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders
Phytotherapy Research, 12/18/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09
Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia
Health Policy, 12/16/09
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Cost Effectiveness and Resource Allocation, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor